Yttrium-90 Ibritumomab Tiuxetan is Cost-Effective Compared to Bendamustine + Rituximab in Low-grade Lymphomas
Titel:
Yttrium-90 Ibritumomab Tiuxetan is Cost-Effective Compared to Bendamustine + Rituximab in Low-grade Lymphomas
Auteur:
Alhaj Moustafa, Muhamad Borah, Bijan J. Moriarty, James P. Dholakia, Ruchita Jiang, Liuyan Li, Ke Witzig, Thomas E. Hoppe, Bradford S. Peterson, Jennifer Cerhan, James R. Tun, Han W